NKTR - ネクタ―・セラピュ―ティクス (Nektar Therapeutics) ネクタ―・セラピュ―ティクス

 NKTRのチャート


 NKTRの企業情報

symbol NKTR
会社名 Nektar Therapeutics (ネクタ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ネクター・セラピューティクス(Nektar Therapeutics)は医薬品を発見・開発するバイオ医薬品企業である。同社の新規治験薬の研究開発パイプラインには、がん、自己免疫疾患、慢性疼痛の治療が含まれる。同社は化学物質のプラットフォームを活用して新薬の候補を発見・設計する。薬物候補は既知の作用機序を標的とする新しい分子実体の開発を可能にするように設計されたポリマーコンジュゲート技術プラットフォームを利用する。同社のプログラムには、免疫腫瘍学(I-O)、免疫学、Pain-NKTR-181、および腫瘍学ONZEALDが含まれる。同社は細胞傷害性T細胞やナチュラルキラー(NK)細胞などの主要な免疫細胞の活性を直接的または間接的に調節してその数を増やし、癌細胞を認識して攻撃する機能を改善するように設計された医薬品を開発する。   ネクタ―・セラピュ―ティクスは、米国の医薬品開発会社。PEG化と高度なポリマ―接合体技術プラットフォ―ムを利用し、薬剤を開発。同社の薬剤候補ナロキセゴ―ルは、オピオイド誘発性便秘の治療に使われる経口末梢性オピオイド拮抗薬で、非癌性疼痛をもつ患者に使われる。その他、「Etirinotecanペゴル」、「NKTR-181」などがある。   
本社所在地 455 Mission Bay Boulevard South San Francisco CA 94158 USA
代表者氏名 Robert B. Chess ロバートB.チェス
代表者役職名 Independent Chairman of the Board
電話番号 +1 415-482-5300
設立年月日 33055
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 509人
url www.nektar.com
nasdaq_url https://www.nasdaq.com/symbol/nktr
adr_tso
EBITDA EBITDA(百万ドル) 959.86200
終値(lastsale) 51.79
時価総額(marketcap) 8932157753.67
時価総額 時価総額(百万ドル) 8261.254
売上高 売上高(百万ドル) 1374.129
企業価値(EV) 企業価値(EV)(百万ドル) 6683.524
当期純利益 当期純利益(百万ドル) 902.71300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Nektar Therapeutics revenues increased from $59.3M to $1.13B. Net income totaled $875.7M vs. loss of $123.7M. Revenues reflect License collaboration and other increase from $10.9M to $1.08B Royalty revenue increase of 34% to $19.6M Non-cash royalty revenue related to sale increase of 20% to $16M. Net Income reflects Other income (expense) net increase from $1.6M to $13.7M (income).

 NKTRのテクニカル分析


 NKTRのニュース

   Leerink Partners Stick to Their Hold Rating for Nektar Therapeutics By Investing.com  2021/04/06 12:25:20 Investing.com
Leerink Partners Stick to Their Hold Rating for Nektar Therapeutics
   Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results  2021/02/28 13:46:45 Transcript Daily
Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.03, MarketWatch Earnings reports. Nektar Therapeutics had a negative net margin of 269.05% and a negative return on equity of 30.74%. During the same quarter in the […]
   Nektar Posts Better-Than-Feared Quarterly Loss, Misses On Revenues  2021/02/26 08:11:58 Smarter Analyst
Nektar Therapeutics reported a better-than-expected loss in the fourth quarter but lagged analysts’ expectations for revenues. Shares of the biopharmaceutical company dropped almost … The post Nektar Posts Better-Than-Feared Quarterly Loss, Misses On Revenues appeared first on Smarter Analyst .
   Nektar Therapeutics Will stock surge before Earnings results? Stock market Insights & financial analysis  2021/02/24 13:28:00 Stock Market Daily
Nektar Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results  2021/02/28 13:46:45 Transcript Daily
Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.03, MarketWatch Earnings reports. Nektar Therapeutics had a negative net margin of 269.05% and a negative return on equity of 30.74%. During the same quarter in the […]
   Nektar Posts Better-Than-Feared Quarterly Loss, Misses On Revenues  2021/02/26 08:11:58 Smarter Analyst
Nektar Therapeutics reported a better-than-expected loss in the fourth quarter but lagged analysts’ expectations for revenues. Shares of the biopharmaceutical company dropped almost … The post Nektar Posts Better-Than-Feared Quarterly Loss, Misses On Revenues appeared first on Smarter Analyst .
   Nektar Therapeutics Will stock surge before Earnings results? Stock market Insights & financial analysis  2021/02/24 13:28:00 Stock Market Daily
Nektar Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   Mizuho Securities Stick to Their Buy Rating for Nektar Therapeutics By Investing.com  2021/02/18 09:15:00 Investing.com
Mizuho Securities Stick to Their Buy Rating for Nektar Therapeutics
   Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Director Sells 1,560 Shares of Stock  2020/12/18 09:28:44 Watchlist News
Nektar Therapeutics (NASDAQ:NKTR) Director Curet Myriam sold 1,560 shares of Nektar Therapeutics stock in a transaction on Tuesday, December 15th. The shares were sold at an average price of $17.82, for a total transaction of $27,799.20. Following the transaction, the director now owns 19,240 shares in the company, valued at approximately $342,856.80. The transaction was […]
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   Nektar Therapeutics EPS beats by $0.16, beats on revenue (NASDAQ:NKTR)  2020/11/05 21:25:05 Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR): Q3 GAAP EPS of -$0.61 beats by $0.16. Revenue of $30M (+2.7% Y/Y) beats by $7.18M.Revenue was higher due to the recognit
   Growing M&A momentum drives gains in Rhenman’s flagship healthcare hedge fund  2020/10/12 11:36:37 Hedgeweek
Growing M&A momentum drives gains in Rhenman’s flagship healthcare hedge fund Submitted By Hugh Leask | 12/10/2020 - 12:36pm A pick-up in M&A activity within certain healthcare stocks is helping Stockholm-based global healthcare-focused hedge fund Rhenman & Partners Asset Management generate further gains in its flagship equity strategy. The Rhenman Healthcare Equity Long/Short hedge fund advanced 4.36 per cent in its euro-denominated share class during September, which brought its year-to-date return to more than 8 per cent. The strategy’s SEK class meanwhile grew 6.14 per cent last month, and is now up 7.59 per cent since the start of 2020. The fund – which trades a range of small, medium and large pharmaceuticals, biotechnology, medical technology and service company names – took profits from positions in Immunomedics and Novocure, while the worst contributors were Nektar Therapeutics and MacroGenics. US biotech firm Immunomedics, which specialises in antibody-based drugs for cancer and autoimmune diseases, attracted a takeover bid from Gilead Sciences at a premium of 108 per cent, corresponding to a company valuation of USD21 billion, which sent its share price soaring. “That also affects similar companies, so we got some nice tailwinds from contributions of similar types of companies,” said CIO and founding partner Henrik Rhenman in a recent webcast, who noted that Immunomedics’ appeal was strengthened by the approval of its promising new cancer drug, sacituzumab govitecan.
   This Is What Hedge Funds Bought And Sold In The Second Quarter  2020/08/16 17:00:00 Zero Hedge
This Is What Hedge Funds Bought And Sold In The Second Quarter Tyler Durden Sun, 08/16/2020 - 13:00 In addition to the widely publicized changes in Berkshire Hathaway's portfolio, where as we previously reported Warren Buffett dumped a material amount of his bank holdings in addition to completely selling out of airlines, while making his first ever foray into precious metals with a new $ 563MM stake in Barrick Gold , there were other quite notable changes in hedge fund portfolios during Q2 as disclosed in the barrage of 13Fs filed on Friday. As Bloomberg recaps, the 13F filings show that even more hedge funds leaned in to the stay-at-home trade amid the Covid-19 pandemic. Of note, Home Depot was a top new buy for Balyasny Asset Management, while Pershing Square Capital Management and Adage Capital Partners boosted stakes in Lowe’s. Coatue Management boosted its stakes in Peloton and Zoom Video Communications. Netflix was one notable exception as Appaloosa, D1 Capital Partners and Viking Global Investors cut their stakes.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ネクタ―・セラピュ―ティクス NKTR Nektar Therapeutics)

 twitter  (公式ツイッターやCEOツイッターなど)